After Novo Nordisk (NVO) reported that subcutaneous amycretin demonstrated up to 22% absolute weight loss at 36-weeks in a Phase 1/2a trial, BofA thinks this “looks potentially best in class.” The firm believes the “solid” data points to a profile similar to CagriSema and able to deliver the 25% weight loss benchmark investors have expected. The firm, which also sees progression to Phase 3 as likely with launch in a FY28 timeframe helping to rebut concerns that have emerged, has a Buy rating and DKK 1,075 price target on Novo Nordisk shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Novo Nordisk Completes Phase 1b/2a Trial for Amycretin
- Novo Nordisk (NYSE:NVO) Stock Surges on Obesity Drug Trial
- Novo Nordisk shares jump on phase 1b/2a subcutaneous amycretin trial results
- Allurion Stock Skyrockets on Weight-Loss Study Buzz
- Viking Therapeutics (VKTX) Stock Could Rise 200%, Says Jefferies